Author:
Hier Jessica,Vachon Olivia,Bernstein Allison,Ibrahim Iman,Mlynarek Alex,Hier Michael,Alaoui-Jamali Moulay A.,Maschietto Mariana,da Silva Sabrina Daniela
Abstract
AbstractIn addition to chronic infection with human papilloma virus (HPV) and exposure to environmental carcinogens, genetic and epigenetic factors act as major risk factors for head and neck cancer (HNC) development and progression. Here, we conducted a systematic review in order to assess whether DNA hypermethylated genes are predictive of high risk of developing HNC and/or impact on survival and outcomes in non-HPV/non-tobacco/non-alcohol associated HNC. We identified 85 studies covering 32,187 subjects where the relationship between DNA methylation, risk factors and survival outcomes were addressed. Changes in DNA hypermethylation were identified for 120 genes. Interactome analysis revealed enrichment in complex regulatory pathways that coordinate cell cycle progression (CCNA1, SFN, ATM, GADD45A, CDK2NA, TP53, RB1 and RASSF1). However, not all these genes showed significant statistical association with alcohol consumption, tobacco and/or HPV infection in the multivariate analysis. Genes with the most robust HNC risk association included TIMP3, DCC, DAPK, CDH1, CCNA1, MGMT, P16, MINT31, CD44, RARβ. From these candidates, we further validated CD44 at translational level in an independent cohort of 100 patients with tongue cancer followed-up beyond 10 years. CD44 expression was associated with high-risk of tumor recurrence and metastasis (P = 0.01) in HPV-cases. In summary, genes regulated by methylation play a modulatory function in HNC susceptibility and it represent a critical therapeutic target to manage patients with advanced disease.
Funder
Canadian Institutes of Health Research
NCORH
Global Affairs Canada
Réseau de Recherche en Santé Buccodentaire et Osseuse
Publisher
Springer Science and Business Media LLC
Reference117 articles.
1. Cancer Research, https://www.cancerresearchuk.org. Accessed May 2020.
2. Silva, S. D., Hier, M., Mlyarek, A., Kowalski, L. P. & Alaoui-Jamali, M. Recurrent oral cancer: Current and emerging therapeutic approaches. Front. Pharmacol. 3, 149 (2012).
3. Canning, M. et al. Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. Front. Cell Dev. Biol. 7, 52. https://doi.org/10.3389/fcell.2019.00052 (2019).
4. Lewis, A., Kang, R., Levine, A. & Maghami, E. The new face of head and neck cancer: The HPV epidemic. Oncology 29, 616–626 (2015).
5. Hashibe, M. et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol. Biomark. Prev. 18, 541–550 (2009).